Cystic fibrosis microbiology: Advances in antimicrobial therapy
- 1 September 2015
- journal article
- review article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 14 (5) , 551-560
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Rate of improvement of CF life expectancy exceeds that of general population—Observational death registration studyJournal of Cystic Fibrosis, 2014
- Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trialJournal of Cystic Fibrosis, 2014
- Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trialJournal of Cystic Fibrosis, 2013
- In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cellsJournal of Antimicrobial Chemotherapy, 2012
- Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosaJournal of Cystic Fibrosis, 2011
- Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patientsDiagnostic Microbiology and Infectious Disease, 2010
- Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic FibrosisChest, 2009
- Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patientsJournal of Clinical Investigation, 2002
- Intermittent Administration of Inhaled Tobramycin in Patients with Cystic FibrosisNew England Journal of Medicine, 1999